FINWIRES · TerminalLIVE
FINWIRES

GRAIL's Galleri Blood Test to Be Evaluated by US FDA Advisory Panel

By

GRAIL (GRAL) said Friday that an advisory panel of the US Food and Drug Administration will convene on Sept. 23 to evaluate the premarket approval application for its Galleri multi-cancer early detection blood test.

The firm submitted the marketing application Jan. 29, incorporating trial results from 25,490 participants in its PATHFINDER 2 study along with over 70,000 subjects from its NHS-Galleri trial, the company said.

Shares of the company were up about 8.9% in Friday trading.

Price: $69.03, Change: $+5.63, Percent Change: +8.88%

Related Articles

Wire

Century Aluminum Q2 Adjusted Earnings, Revenue Rise

Century Aluminum (CENX) reported Q2 adjusted earnings late Thursday of $2.46 per diluted share, up from $0.30 a year earlier.Three analysts polled by FactSet expected $2.33.Revenue for the three months ended June 30 rose to $752.1 million from $628.1 million a year earlier.Four analysts surveyed by FactSet expected $817.2 million.The company's shares rose 1.6% in after-hours trading.

$CENX
Wire

JFrog Q2 Non-GAAP Earnings, Revenue Rise; Shares Gain After Hours

JFrog (FROG) reported Q2 non-GAAP earnings late Thursday of $0.27 per diluted share, up from $0.18 a year earlier.Analysts polled by FactSet expected $0.24.Revenue in the three months ended June 30 rose to $163.8 million from $127.2 million a year earlier.Analysts projected $155.6 million.The company expects Q3 non-GAAP EPS of $0.22 to $0.24 on revenue of $164 million to $166 million. Analysts project EPS of $0.22 on revenue of $159 million.JFrog boosted full-year guidance to non-GAAP EPS of $0.96 to $1.00 on revenue of $648 million to $652 million. The prior forecast was EPS of $0.93 to $0.97 on revenue of $628 million to $632 million.Analysts expect EPS of $0.95 on revenue of $632.9 million.JFrog shares jumped 13% in after-hours trading.

$FROG
Wire

Reinsurance Group of America Q2 Adjusted Earnings, Revenue Rise

Reinsurance Group of America (RGA) reported Q2 adjusted earnings late Thursday of $8.89 per diluted share, up from $4.72 a year earlier.Analysts polled by FactSet expected $6.50.Revenue in the three months ended June 30 rose to $6.64 billion from $5.6 billion a year earlier.Analysts projected $6.67 billion.The company's shares rose 1.6% in after-hours trading.

$RGA